

**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012



## **SAFETY DATA SHEET**

### **Section 1. Identification of the substance/mixture and of the company/undertaking**

#### **1.1 Product Identifier**

**Product Name:** Norethindrone Acetate Tablets

**List Number:** 1049

#### **1.2 Relevant identified uses of the substance or mixture and uses advised against**

**Recommended use:** Pharmaceuticals

#### **1.3 Details of the supplier of the safety data sheet**

**Supplier:** Manufactured for:  
Abbott Laboratories  
100 Abbott Park Road  
Abbott Park, IL 60064  
USA

**E-mail Address:** Abbott.SDS@abbott.com

#### **1.4 Emergency telephone number**

**Emergency Telephone:** CHEMTREC: 1(800) 424-9300 (in USA and Canada)  
or +1-703-527-3887 (international)

### **Section 2. Hazards identification**

#### **2.1 Classification of the substance or mixture**

**Regulation (EC) No 1272/2008**

**Reproductive toxicity** Category 1B

**Carcinogenicity** Category 2

**Classification according to EU Directives 67/548/EEC or 1999/45/EC**

**Risk Phrases:** R40 - Limited evidence of a carcinogenic effect  
R60 - May impair fertility  
R61 - May cause harm to the unborn child

#### **2.2 Label elements**



**Signal Word:** Danger

**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012

**Hazard Statements:** H351 - Suspected of causing cancer  
H360 - May damage fertility or the unborn child

**Precautionary Statements:** P201 - Obtain special instructions before use  
P202 - Do not handle until all safety precautions have been read and understood  
P281 - Use personal protective equipment as required  
P308 + P313 - IF exposed or concerned: Get medical advice/attention  
P405 - Store locked up  
P501 - Dispose of contents/container to an approved waste disposal plant

### 2.3 Other hazards

Not determined

## **Section 3. Composition/information on ingredients**

Chemical Name	Percent	EINECS/ELINCS Number	EEC Classification	EU - GHS Substance Classification	REACH No.
Lactose monohydrate 10039-26-6	70-90	NA		Not Hazardous*	No data available
Cellulose Microcrystalline 9004-34-6	5-20	232-674-9		Not Hazardous*	No data available
Norethindrone acetate 51-98-9	1-10	200-132-0	R40 R60, R61	Carc. 2 (H351) Repr. 1B (H360)	No data available
Magnesium Stearate 557-04-0	1-10	209-150-3		Not Hazardous*	No data available
Talc, Nonasbestos Containing 14807-96-6	1-10	238-877-9		Not Hazardous*	No data available

Not Hazardous\* - Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

**For the full text of the R-phrases mentioned in this Section, see Section 16**  
**For the full text of the H-Statements mentioned in this Section, see Section 16**

## **Section 4. First aid measures**

### 4.1 Description of first aid measures

**Eye Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Skin Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Inhalation:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Ingestion:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012

**Protection of First-aiders:** Use personal protective equipment

#### **4.2 Most important symptoms and effects, both acute and delayed**

**Signs and Symptoms:** Available information support the following: altered menstrual function, headaches, nausea, dizziness.

**Medical Conditions Aggravated by Exposure:** None known from occupational exposure.

#### **4.3 Indication of any immediate medical attention and special treatment needed**

**Notes To Physician:** Treat symptomatically

### **Section 5. Firefighting measures**

#### **5.1 Extinguishing Media**

**Suitable Extinguishing Media:** Use extinguishing agent suitable for type of surrounding fire

**Unsuitable Extinguishing Media:** Not determined

#### **5.2 Special hazards arising from the substance or mixture**

**Special Exposure Hazards:** Not determined

#### **5.3 Advice for firefighters**

**Protective Equipment and Precautions for Firefighters:** As in any fire, wear self-contained breathing apparatus and full protective gear

### **Section 6. Accidental release measures**

#### **6.1. Personal precautions, protective equipment and emergency procedures**

**Personal Precautions:** For personal protection see section 8

#### **6.2. Environmental precautions**

**Environmental Precautions:** Contain material and prevent release to waterways or soil.

#### **6.3. Methods and material for containment and cleaning up**

**Methods for Cleaning Up:** Recover product and place in an appropriate container for disposal.

#### **6.4. Reference to other sections**

Refer to Sections 8, 12, and 13 for further information.

### **Section 7. Handling and storage**

#### **7.1. Precautions for safe handling**

Handle in accordance with good industrial hygiene and safety practice

#### **7.2. Conditions for safe storage, including any incompatibilities**

**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012

Store according to label instructions

**7.3. Specific end use(s)**

**Recommended use:** Pharmaceuticals

**Section 8. Exposure controls/personal protection**

**8.1. Control parameters**

**Exposure limits:**

Chemical Name	Abbott EEL	Skin Notation
Lactose monohydrate 10039-26-6	Not Applicable	None
Cellulose Microcrystalline 9004-34-6	Not Applicable	None
Norethindrone acetate 51-98-9	Not Applicable	None
Magnesium Stearate 557-04-0	Not Applicable	None
Talc, Nonasbestos Containing 14807-96-6	Not Applicable	None

Chemical Name	ACGIH TLV	France	German MAK	Ireland	Italy
Cellulose Microcrystalline 9004-34-6	10 mg/m <sup>3</sup> total dust	TWA: 10 mg/m <sup>3</sup>		20 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)	
Magnesium Stearate 557-04-0	10 mg/m <sup>3</sup> total dust				
Talc, Nonasbestos Containing 14807-96-6	2 mg/m <sup>3</sup> , respirable dust			10 mg/m <sup>3</sup> (TWA) 0.8 mg/m <sup>3</sup> (TWA)	

Chemical Name	The Netherlands	Spain	Switzerland	UK OEL/MEL
Cellulose Microcrystalline 9004-34-6		10 mg/m <sup>3</sup> (TWA)	3 mg/m <sup>3</sup> (TWA)	20 mg/m <sup>3</sup> (STEL) 12 mg/m <sup>3</sup> (STEL) 20 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)
Talc, Nonasbestos Containing 14807-96-6	0.25 mg/m <sup>3</sup> (TWA)	2 mg/m <sup>3</sup> (TWA)	2 mg/m <sup>3</sup> (TWA)	3 mg/m <sup>3</sup> (STEL) 1 mg/m <sup>3</sup> (TWA)

**8.2. Exposure controls**

**Engineering Controls:** No special provisions are required under normal product use conditions. Use inside a process enclosure when handling the bulk formulation.

**Respiratory Protection:** Respiratory protection is not needed during normal product use. When handling the bulk formulation, an approved respirator (i.e. NIOSH, EN, etc.) should be worn when exposures are expected to exceed the applicable limits.

**Eyes:** Eye protection not needed during typical product use conditions. Wear eye protection as appropriate when handling the bulk formulation.

**Gloves:** Gloves not required during normal product use conditions. Wear impervious gloves when handling the bulk formulation.

**Other PPE Data:** Wear appropriate body coverings if contact may occur.

**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012

**Environmental Exposure Controls:** Not determined

## **Section 9. Physical and chemical properties**

### **9.1. Information on basic physical and chemical properties**

<b>Appearance:</b>	White to off-white Oval tablet
<b>Odor:</b>	Not determined.
<b>Odor Threshold:</b>	Not determined
<b>pH:</b>	Not determined.
<b>Boiling Pt. @ 760 mm Hg (°C):</b>	Not determined.
<b>Melting/Freezing Point (°C):</b>	Not determined
<b>Flash Point (°C):</b>	Not determined.
<b>Evaporation Rate at 20°C:</b>	Not determined.
<b>Flammability (Solid):</b>	Not determined.
<b>Lower Explosive Limit:</b>	Not determined.
<b>Upper Explosive Limit:</b>	Not determined.
<b>Vapor Pressure (mm Hg):</b>	Not determined.
<b>Vapor Density (Air = 1):</b>	Not determined.
<b>Specific Gravity:</b>	Not determined.
<b>Solubility(ies):</b>	Not determined.
<b>Partition coefficient: n-octanol/water</b>	Not determined.
<b>Autoignition Temp. (°C):</b>	Not determined.
<b>Decomposition temperature (°C):</b>	Not determined.
<b>Viscosity (centipoise):</b>	Not determined.
<b>Explosion Severity:</b>	Not determined.
<b>Oxidizer Properties:</b>	Not determined.

### **9.2. Other information**

Not determined

## **Section 10. Stability and reactivity**

### **10.1. Reactivity**

Not determined

### **10.2. Chemical stability**

Stable under normal conditions

### **10.3. Possibility of hazardous reactions**

**Hazardous reactions:** Not determined.

### **10.4. Conditions to avoid**

Not determined.

### **10.5 Incompatible materials**

**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012

Not determined

### 10.6 Hazardous decomposition products

Carbon oxides, Nitrogen oxides (NOx)

## Section 11. Toxicological information

### 11.1. Information on toxicological effects

#### Routes of Exposure:

**Oral:** Clinical Route  
**Dermal:** Yes  
**Inhalation:** Unlikely

**Acute Toxicity - Oral:** Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Lactose monohydrate 10039-26-6	LD50 >	10000	mg/kg, for a similar material	Rats
Cellulose Microcrystalline 9004-34-6	LD50 >	5000	mg/kg	Rats
Norethindrone acetate 51-98-9	LD50 >	5000	mg/kg	Rats Mice

**Acute Toxicity - Dermal:** Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Cellulose Microcrystalline 9004-34-6	LD50 >	2000	mg/kg	Rabbits

**Acute Toxicity - Inhalation:** Data for component (s) given below.

Chemical Name	Test	Value	Units	Species
Cellulose Microcrystalline 9004-34-6	LC 50 >	5800	mg/m <sup>3</sup> , 4 hour	Rats
Magnesium Stearate 557-04-0	LC 50 >	2000	mg/m <sup>3</sup> , 1 hour	Rats

**Corrosivity:** Not determined.

**Dermal Irritation:** Not determined.

**Eye Irritation:** Not determined.

**Sensitization:** Not determined.

**Toxicokinetics/Metabolism:** Not determined.

**Target Organ Effects:** Not determined.

**Reproductive Effects:** Active Ingredient : In animals adverse reproductive effects include: reduced fertility in females, fetal toxicity, fetal abnormalities.

**Carcinogenicity:** Data for component(s) given below.

Chemical Name	Site of Tumors	Species	Dosage	Route	Units	Duration
Norethindrone acetate 51-98-9	Liver Female Reproductive System	Rats	3-4	Oral	mg/kg	2 years

**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012

Chemical Name	Site of Tumors	Species	Dosage	Route	Units	Duration
Talc, Nonasbestos Containing 14807-96-6	Lungs	Rats	18	Inhalation	mg/m <sup>3</sup> , 6 hours	2 years

**Mutagenicity:** Data for component (s) given below.

Chemical Name	Micronucleus Assay	Ames Test:	Mouse Lymphoma Assay	Chromosomal Abbr. Assay
Lactose monohydrate 10039-26-6	No Data.	Negative	No Data.	Negative
Norethindrone acetate 51-98-9	No Data.	Negative	No Data.	Positive
Magnesium Stearate 557-04-0	No Data.	Negative	No Data.	No Data.

**Aspiration hazard:** Not determined

**Notes:**

1. ALD: Approximate lethal dosage
2. LC50: Concentration in air that produces 50% mortality
3. LD50: Oral or dermal dosage that produces 50% mortality

## Section 12. Ecological information

### 12.1. Toxicity

Not determined.

### 12.2. Persistence and degradability

Not determined.

### 12.3. Bioaccumulative potential

Not determined

### 12.4. Mobility in soil

Not determined.

### 12.5. Results of PBT or vPvB assessment

Chemical safety report is not required for this substance/product.

### 12.6. Other adverse effects

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

**Notes:**

1. EC50: Concentration in water that produces 50% mortality in *Daphnia* sp.
2. LC50: Concentration in water that produces 50% mortality in fish.
3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.

## Section 13. Disposal considerations

### 13.1 Waste treatment methods

**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012

**Waste Disposal Methods:** Disposal should be made in accordance with country, federal, state and local regulations.

## Section 14. Transport information

### ADR, DOT, ICAO/IATA, IMDG/IMO

**Status:** Not regulated

**14.1. UN Number:** Not applicable

**14.2. Proper shipping name:** Not applicable

**14.3. Hazard class:** Not applicable

**14.4. Packing group:** Not applicable

**14.5. Environmental hazard:** Not applicable

**14.6. Special Provisions:** Not applicable

**14.7. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code:** Not applicable

## Section 15. Regulatory Information

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### International Inventories

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Lactose monohydrate 10039-26-6	-	-	-	Not listed.	-
Cellulose Microcrystalline 9004-34-6	232-674-9	X	X	Not listed.	X
Norethindrone acetate 51-98-9	200-132-0	-	X	Not listed.	-
Magnesium Stearate 557-04-0	209-150-3	X	X	Not listed.	X
Talc, Nonasbestos Containing 14807-96-6	238-877-9	X	X	Not listed.	X

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Lactose monohydrate 10039-26-6	-	-	X	X	-	
Cellulose Microcrystalline 9004-34-6	(8)-568	-	X	X	KE-05339	
Norethindrone acetate 51-98-9	-	7-(1)-266	-	X	KE-20747	
Magnesium Stearate 557-04-0	(2)-611	-	X	X	KE-26390	
Talc, Nonasbestos Containing 14807-96-6	(1)-468	-	X	X	KE-32773	

#### **Legend**

**EINECS/ELINCS** - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**ISHL** - Japan Industrial Safety and Health Law

**IECSC** - China Inventory of Existing Chemical Substances

**AICS** - Australian Inventory of Chemical Substances



**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012

KECL - Korean Existing and Evaluated Chemical Substances

**Carcinogenicity Rating:**

Chemical Name	Percent	NTP:	IARC:	ACGIH:
Lactose monohydrate	70-90	Not Listed	Not Listed	Not Listed
Cellulose Microcrystalline	5-20	Not Listed	Not Listed	Not Listed
Norethindrone acetate	1-10	Not Listed	Not Listed	Not Listed
Magnesium Stearate	1-10	Not Listed	Not Listed	Not Listed
Talc, Nonasbestos Containing	1-10	Not Listed	Not Listed	Not Listed

**SARA 313 Information**

Chemical Name	Percent	SARA 313 Chemical:	CERCLA RQ/SARA EHS RQ (lbs):	SARA EHS TPQ (lbs):
Lactose monohydrate	70-90	No	Not Applicable	Not applicable
Cellulose Microcrystalline	5-20	No	Not Applicable	Not applicable
Norethindrone acetate	1-10	No	Not Applicable	Not applicable
Magnesium Stearate	1-10	No	Not Applicable	Not applicable
Talc, Nonasbestos Containing	1-10	No	Not Applicable	Not applicable

**Immediate Health:** Yes  
**Delayed Health:** No  
**Fire:** No  
**Sudden Pressure:** No  
**Reactivity:** No

**RCRA Status:** Not determined.

**Proposition 65 Status:** Chemicals known to the State of California to cause cancer or reproductive harm listed below.

Chemical Name	Percent	Proposition 65 Listed Materials
Norethindrone acetate	1-10	Cancer and Reproduction

**WHMIS Hazard Class:** Not determined.

**NFPA Rating:**  
 Health: 1  
 Fire: 1  
 Reactivity: 0

**Notes:**

1. SARA = Superfund Amendments and the Reauthorization Act.
2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.
3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.
4. TSCA = Toxic Substances Control Act.
5. EC = European Community.
6. WHMIS = Canadian Workplace Hazardous Materials Information System.
7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

**15.2. Chemical safety assessment**

Chemical safety assessment has not been conducted on the substance/product.

**Section 16. Other information**

**Risk Phrases:** R40 - Limited evidence of a carcinogenic effect , R60 - May impair fertility, R61 - May cause harm to the unborn child

**Product Name:** Norethindrone Acetate Tablets  
**Issued:** Apr-04-2012

**Full text of H-Statements referred to under sections 2 and 3**

H351 - Suspected of causing cancer if inhaled, H360 - May damage fertility or the unborn child if inhaled

**Document Authored By:** Global Occupational Toxicology (D-03QC)

**Issued:** Apr-04-2012

**Disclaimer:**

*The information and recommendations contained herein are based upon tests believed to be reliable. However, Abbott Laboratories does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Abbott Laboratories assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.*